Market Assessment and Capacity Planning for Pancreatic Cancer CDMO Entry
A global Contract Development and Manufacturing Organization (CDMO) sought Stellarix’s support to assess the strategic and financial viability of pancreatic cancer-focused manufacturing devices. Our strategic intelligence enabled demand-driven capacity planning and informed market entry through effective risk mitigation and clear market visibility. Client Background: A global Contract Development and Manufacturing Organization (CDMO) intended to evaluate […]
IP Landscape – mRNA Characterization
A leading global biopharma company sought a comprehensive IP landscape review to identify market gaps and enhance its competitive edge. Stellarix’s consulting insights helped the client expand into new markets and strategically position their IP portfolio by highlighting high-value technologies and untapped areas for patent filing. Client Background: A global biopharma leader focused on immune […]
In-Vivo CAR-T Cell Therapy: The Next Chapter in Oncology
Cell Therapy: Cancer’s New Arsenal Though several therapeutic, biotech, and medtech developments are changing the oncology landscape, in-vivo CAR-T cell therapy stands out for its precision, accessibility, and upscaling capabilities. A step up from ex vivo CAR-T cell therapy, it takes precedence due to its improved toxicity management, manufacturing parameters, and broader scope of clinical […]
In-vivo CAR-T Cell Therapy: New Frontier in Cancer Treatment
Chimeric antigen receptor T-cell (CAR-T) therapy transformed oncology by paving the path for harnessing patients’ own cells to treat B-cell lymphomas, leukemias, and other hematological malignancies. Traditionally, CAR-T cell therapy for cancer relied on ex vivo processes, where a patient’s T-cells are extracted, genetically reprogrammed in an external medium to express synthetic receptors targeting cancer […]
Technology Overview & Start-up Scouting for Development of Allogeneic iPSCs
A clinical-stage biopharmaceutical company approached Stellarix to get a technology and innovation overview in the allogeneic iPSCs segment. Our strategic intelligence helped the client gain a future outlook on allogeneic iPSCs development with HLA/MHC knockdown, reforming its market and business strategy. Client Background: Clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent […]
IP Landscape- Lipid Nanoparticles for Biomolecules Delivery
A global pharmaceutical leader partnered with Stellarix to gain strategic insights into lipid nanoparticle (LNP) systems for biomolecule delivery. With LNPs emerging as a critical platform for mRNA, siRNA, and CRISPR-based therapeutics, recognized and regulated by the FDA—our case study mapped key components, formulation strategies, and advanced manufacturing practices. Client Background: The client is a […]
The Expanding Role Of Self-Amplifying RNA In Therapeutics
The approval of KOSTAIVE by Arcturus Therapeutics and CSL by the European Medicines Agency (EMA) marked the next chapter in the growing impact of mRNA vaccines worldwide. KOSTAIVE, however, is also a step ahead of the traditional mRNA vaccines. It is embedded with self-amplifying RNA (saRNA) that supersedes its standard counterpart in several ways. Though […]
Pricing Analysis of a New Drug
A biopharma industry leader with potential candidates in a phase III trial for neurological and cardiovascular diseases was interested in making a pricing decision. The engagement included understanding competitor drug positioning along with efficacy study analysis to provide better insights on price points for clients. Client Background: The client is one of the key players […]